{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:58:42Z","timestamp":1791932322418,"version":"4.3.4"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jvacx.2019.100009","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T06:01:22Z","timestamp":1548828082000},"page":"100009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["rVSV\u0394G-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk\/benefit assessment"],"prefix":"10.1016","volume":"1","author":[{"given":"Thomas P.","family":"Monath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia E.","family":"Fast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayvon","family":"Modjarrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Gray","family":"Heppner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub K.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Troth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanthi","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidisha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth-Ann","family":"Coller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2019.100009_b0005","series-title":"Replicating vaccines","first-page":"47","article-title":"Classical live vaccines","author":"Monath","year":"2011"},{"key":"10.1016\/j.jvacx.2019.100009_b0010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1128\/CMR.00005-07","article-title":"Current status of veterinary vaccines","volume":"20","author":"Meeusen","year":"2007","journal-title":"Curr Microbiol Rev"},{"key":"10.1016\/j.jvacx.2019.100009_b0015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s11262-017-1486-3","article-title":"Vaccine platform recombinant measles virus","volume":"53","author":"M\u00fchlenbach","year":"2017","journal-title":"Virus Genes"},{"key":"10.1016\/j.jvacx.2019.100009_b0020","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S1473-3099(12)70345-6","article-title":"Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study","volume":"13","author":"Gurwith","year":"2013","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.jvacx.2019.100009_b0025","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1128\/JVI.00065-11","article-title":"Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype","volume":"85","author":"Kim","year":"2011","journal-title":"J Virol."},{"key":"10.1016\/j.jvacx.2019.100009_b0030","series-title":"Replicating vaccines. Birkh\u00e4user advances in infectious diseases","first-page":"349","article-title":"Recombinant, chimeric, live, attenuated vaccines against flaviviruses and alphaviruses","author":"Monath","year":"2011"},{"key":"10.1016\/j.jvacx.2019.100009_b0035","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2217\/imt.15.110","article-title":"Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector","volume":"8","author":"Quinn","year":"2016","journal-title":"Immunotherapy."},{"key":"10.1016\/j.jvacx.2019.100009_b0040","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1016\/j.vaccine.2016.06.071","article-title":"Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: standardized template with key considerations for a risk\/benefit assessment","volume":"34","author":"Clarke","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2019.100009_b0045","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/pds.851","article-title":"The Brighton Collaboration: enhancing comparability of vaccine safety data","volume":"12","author":"Kohl","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jvacx.2019.100009_b0050","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.vaccine.2014.09.035","article-title":"The Brighton Collaboration viral vector vaccines safety working group (V3SWG)","volume":"33","author":"Chen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2019.100009_b0055","doi-asserted-by":"crossref","first-page":"e01729","DOI":"10.1128\/JVI.01729-16","article-title":"Recombinant Isfahan virus and vesicular stomatitis virus vaccine vectors provide durable, multivalent, single-dose protection against lethal alphavirus challenge","volume":"91","author":"Nasar","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2019.100009_b0060","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/mt.2013.249","article-title":"Maraba virus as a potent oncolytic vaccine vector","volume":"22","author":"Pol","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.jvacx.2019.100009_b0065","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11262-014-1160-y","article-title":"Using rabies virus vaccine strain SRV9 as viral vector to express exogenous gene","volume":"50","author":"Wang","year":"2015","journal-title":"Virus Genes"},{"key":"10.1016\/j.jvacx.2019.100009_b0070","article-title":"Vesicular stomatitis virus-vectored multi-antigen tuberculosis vaccine limits bacterial proliferation in mice following a single intranasal dose","author":"Zhang","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jvacx.2019.100009_b0075","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ijrobp.2015.07.2274","article-title":"Definitive management of oligometastatic melanoma in a murine model using combined ablative radiation therapy and viral immunotherapy","volume":"93","author":"Blanchard","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Pt 8","key":"10.1016\/j.jvacx.2019.100009_b0080","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1099\/vir.0.065201-0","article-title":"Pseudotyping of vesicular stomatitis virus with the envelope glycoproteins of highly pathogenic avian influenza viruses","volume":"95","author":"Zimmer","year":"2014","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jvacx.2019.100009_b0085","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1016\/j.vaccine.2014.02.087","article-title":"Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins","volume":"32","author":"DeBuysscher","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2019.100009_b0090","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1128\/JVI.78.10.5458-5465.2004","article-title":"Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses","volume":"78","author":"Garbutt","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2019.100009_b0095","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1128\/JVI.00561-09","article-title":"Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus","volume":"83","author":"Geisbert","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2019.100009_b0100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/JVI.02265-13","article-title":"Characterization of the envelope glycoprotein of a novel filovirus, Lloviu virus","volume":"88","author":"Maruyama","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2019.100009_b0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/vim.2014.0068","article-title":"The multiple roles of sGP in Ebola pathogenesis","volume":"28","author":"de La Vega","year":"2015","journal-title":"Viral Immunol"},{"key":"10.1016\/j.jvacx.2019.100009_b0110","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1128\/JVI.00101-16","article-title":"Chimeric filoviruses for identification and characterization of monoclonal antibodies","volume":"90","author":"Ilinykh","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2019.100009_b0115","doi-asserted-by":"crossref","first-page":"46374","DOI":"10.1038\/srep46374","article-title":"Structure of the Ebola virus glycoprotein spike within the virion envelope at 11 \u00c5 resolution","volume":"7","author":"Beniac","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jvacx.2019.100009_b0120","doi-asserted-by":"crossref","first-page":"e00862-13","DOI":"10.1128\/mBio.00862-13","article-title":"Comprehensive functional analysis of N-linked glycans on Ebola virus GP1","volume":"5","author":"Lennemann","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.jvacx.2019.100009_b0125","doi-asserted-by":"crossref","first-page":"e00479","DOI":"10.1128\/JVI.00479-17","article-title":"Vesicular stomatitis virus pseudotyped with Ebola virus glycoprotein serves as a protective, noninfectious vaccine against Ebola virus challenge in mice","volume":"91","author":"Lenneman","year":"2017","journal-title":"J Virol."},{"key":"10.1016\/j.jvacx.2019.100009_b0130","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1080\/21645515.2017.1412898","article-title":"Assessment of the ability of V920 recombinant vesicular stomatitis-Zaire ebolavirus vaccine to replicate in arthropod cell cultures of relevant vector species and in relevant vector species","volume":"14","author":"Bergren","year":"2018","journal-title":"Hum Vacc Immunother"},{"key":"10.1016\/j.jvacx.2019.100009_b0135","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/v3081501","article-title":"Intracellular events and cell fate in filovirus infection","volume":"3","author":"Olejnik","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.jvacx.2019.100009_b0140","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jvacx.2019.100009_b0145","doi-asserted-by":"crossref","first-page":"e61904","DOI":"10.1371\/journal.pone.0061904","article-title":"Immunopathogenesis of severe acute respiratory disease in Zaire ebolavirus-infected pigs","volume":"8","author":"Nfon","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jvacx.2019.100009_b0150","doi-asserted-by":"crossref","first-page":"6268","DOI":"10.1016\/j.vaccine.2015.09.069","article-title":"Assessment of a novel recombinant vesicular stomatitis virus with triple mutations in its matrix protein as a vaccine for pigs","volume":"33","author":"Fang","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2019.100009_b0155","doi-asserted-by":"crossref","first-page":"e1001121","DOI":"10.1371\/journal.ppat.1001121","article-title":"Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner","volume":"6","author":"Nanbo","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jvacx.2019.100009_b0160","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0022-2836(82)90269-8","article-title":"Pathway of vesicular stomatitis virus entry leading to infection","volume":"156","author":"Matlin","year":"1982","journal-title":"J Mol Biol"},{"key":"10.1016\/j.jvacx.2019.100009_b0165","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1099\/vir.0.81199-0","article-title":"Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization","volume":"86","author":"Ji","year":"2005","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jvacx.2019.100009_b0170","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature10348","article-title":"Ebola virus entry requires the cholesterol transporter Niemann-Pick C1","volume":"477","author":"Carette","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jvacx.2019.100009_b0175","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.tim.2016.05.008","article-title":"Feverish quest for Ebola immunotherapy: straight or cocktail?","volume":"24","author":"Saphire","year":"2016","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.jvacx.2019.100009_b0180","doi-asserted-by":"crossref","first-page":"16128","DOI":"10.1038\/nmicrobiol.2016.128","article-title":"Structures of Ebola virus GP and sGP in complex with therapeutic antibodies","volume":"1","author":"Pallesen","year":"2016","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jvacx.2019.100009_b0185","doi-asserted-by":"crossref","first-page":"e1567","DOI":"10.1371\/journal.pntd.0001567","article-title":"Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates","volume":"6","author":"Mire","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.jvacx.2019.100009_b0190","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.celrep.2017.08.023","article-title":"Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the Ebola vaccine rVSV-ZEBOV","volume":"20","author":"Rechtien","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.jvacx.2019.100009_b0195","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jvacx.2019.100009_b0200","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.aad6117","article-title":"Structural and molecular basis for Ebola virus neutralization by protective human antibodies","volume":"351","author":"Misasi","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jvacx.2019.100009_b0205","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.celrep.2017.03.049","article-title":"Cooperativity non-neutralizing antibodies to neutralize ebolavirus","volume":"19","author":"Howell","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.jvacx.2019.100009_b0210","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP\u2013mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc Natl Acad Med (USA)"},{"key":"10.1016\/j.jvacx.2019.100009_b0215","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ebiom.2017.03.045","article-title":"Dose-dependent T-cell dynamics and cytokine cascade following rVSV-ZEBOV immunization","volume":"19","author":"Dahlke","year":"2017","journal-title":"EBioMedicine"},{"issue":"35 Pt A","key":"10.1016\/j.jvacx.2019.100009_b0220","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1016\/j.vaccine.2017.05.097","article-title":"Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic","volume":"35","author":"Coller","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2019.100009_b0225","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S1473-3099(17)30313-4","article-title":"Safety and immunogenicity of the rVSV\u0394G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study","volume":"17","author":"Heppner","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jvacx.2019.100009_b0230","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvacx.2019.100009_b0235","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"rVSV EBOLA vaccine: phase I trials in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvacx.2019.100009_b0240","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jvacx.2019.100009_b0245","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jvacx.2019.100009_b0250","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJM196711092771901","article-title":"Human infection with the virus of vesicular stomatitis during an epizootic","volume":"277","author":"Fields","year":"1967","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvacx.2019.100009_b0255","series-title":"Rhabdoviridae, Field\u2019s Virology","author":"Fields","year":"2007"},{"key":"10.1016\/j.jvacx.2019.100009_b0260","first-page":"1081","article-title":"Prevalence of human infection with vesicular stomatitis virus","volume":"40","author":"Shelokov","year":"1961","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jvacx.2019.100009_b0265","doi-asserted-by":"crossref","first-page":"847","DOI":"10.4269\/ajtmh.1988.39.312","article-title":"A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection","volume":"39","author":"Quiroz","year":"1988","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jvacx.2019.100009_b0270","first-page":"754","article-title":"Human infection with the virus of vesicular stomatitis","volume":"36","author":"Hanson","year":"1950","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.jvacx.2019.100009_b0275","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4269\/ajtmh.1966.15.244","article-title":"Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV)","volume":"15","author":"Johnson","year":"1966","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jvacx.2019.100009_b0280","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oxfordjournals.aje.a121068","article-title":"Ecologic studies of vesicular stomatitis virus. I. Prevalence of infection among animals and humans living in an area of endemic VSV activity","volume":"90","author":"Tesh","year":"1969","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jvacx.2019.100009_b0285","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4269\/ajtmh.1987.36.177","article-title":"Epizootic Vesicular Stomatitis in Colorado, 1982: infection in occupational risk groups","volume":"36","author":"Reif","year":"1987","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jvacx.2019.100009_b0290","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2105\/AJPH.47.2.205","article-title":"Epizootiology of vesicular stomatitis","volume":"47","author":"Hanson","year":"1957","journal-title":"Am J Pub Hlth"},{"key":"10.1016\/j.jvacx.2019.100009_b0295","first-page":"395","article-title":"Chandipura virus encephalitis outbreak among children in Nagpur Division, Maharashtra, 2007","volume":"132","author":"Gurav","year":"2010","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.jvacx.2019.100009_b0300","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-065X.1995.tb00090.x","article-title":"Immune defence in mice lacking type I and\/or type II interferon receptors","volume":"148","author":"van den Broek","year":"1995","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jvacx.2019.100009_b0305","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/104063879700900205","article-title":"Experimental vesicular stomatitis in swine: effects of route of inoculation and steroid treatment","volume":"9","author":"Howerth","year":"1997","journal-title":"J Vet Diagn Invest"},{"issue":"Suppl. 2","key":"10.1016\/j.jvacx.2019.100009_b0310","doi-asserted-by":"crossref","first-page":"S404","DOI":"10.1086\/520591","article-title":"Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever","volume":"196","author":"Jones","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jvacx.2019.100009_b0315","series-title":"Diseases transmitted from animals to man","first-page":"897","article-title":"Vesicular stomatitis","author":"Tesh","year":"1975"},{"key":"10.1016\/j.jvacx.2019.100009_b0320","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1051\/vetres:2007001","article-title":"Vesicular stomatitis New Jersey virus (VSNJV) infects keratinocytes and is restricted to lesion sites and local lymph nodes in the bovine, a natural host","volume":"38","author":"Scherer","year":"2007","journal-title":"Vet Res"},{"key":"10.1016\/j.jvacx.2019.100009_b0325","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/tvjl.1998.0303","article-title":"Vesicular stomatitis","volume":"157","author":"Letchworth","year":"1999","journal-title":"Vet J"},{"key":"10.1016\/j.jvacx.2019.100009_b0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2014.10.035","article-title":"Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector","volume":"475","author":"Wollmann","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.jvacx.2019.100009_b0335","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1016\/j.vaccine.2009.03.006","article-title":"In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation","volume":"27","author":"Johnson","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2019.100009_b0340","doi-asserted-by":"crossref","first-page":"10920","DOI":"10.1128\/JVI.78.20.10920-10926.2004","article-title":"Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus","volume":"78","author":"Coil","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2019.100009_b0345","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.virusres.2013.06.003","article-title":"Understanding and altering cell tropism of vesicular stomatitis virus","volume":"176","author":"Hastie","year":"2013","journal-title":"Virus Res"},{"key":"10.1016\/j.jvacx.2019.100009_b0355","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1073\/pnas.1214441110","article-title":"LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus","volume":"110","author":"Finkelshtein","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jvacx.2019.100009_b0360","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1128\/JVI.02167-06","article-title":"Persistent antigen presentation after acute vesicular stomatitis virus infection","volume":"81","author":"Turner","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2019.100009_b0365","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/ni.2169","article-title":"Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus","volume":"13","author":"Honke","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jvacx.2019.100009_b0370","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1089\/vim.2004.17.516","article-title":"Vesicular stomatitis virus as an oncolytic vector","volume":"17","author":"Barber","year":"2004","journal-title":"Viral Immunol"},{"key":"10.1016\/j.jvacx.2019.100009_b0375","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/viro.2001.1329","article-title":"Matrix protein mutations contribute to inefficient induction of apoptosis leading to persistent infection of human neural cells by vesicular stomatitis virus","volume":"295","author":"Desforges","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.jvacx.2019.100009_b0380","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1099\/0022-1317-33-2-193","article-title":"Long-term persistent vesicular stomatitis virus and rabies virus infection of cells in vitro","volume":"33","author":"Holland","year":"1976","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jvacx.2019.100009_b0385","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1099\/0022-1317-63-2-493","article-title":"Vesicular stomatitis virus can establish persistent infections in Syrian hamsters","volume":"63","author":"Fultz","year":"1982","journal-title":"J Gen Virol"},{"issue":"3","key":"10.1016\/j.jvacx.2019.100009_b0390","doi-asserted-by":"crossref","first-page":"621","DOI":"10.4269\/ajtmh.1983.32.621","article-title":"Growth and transovarial transmission of Chandipura virus (Rhabdoviridae: Vesiculovirus) in Phlebotomus papatasi","volume":"32","author":"Tesh","year":"1983","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jvacx.2019.100009_b0395","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/oxfordjournals.aje.a121130","article-title":"Ecologic studies of vesicular stomatitis virus. II. Results of experimental infection in Panamanian wild animals","volume":"91","author":"Tesh","year":"1970","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jvacx.2019.100009_b0400","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4269\/ajtmh.1987.36.653","article-title":"Natural infection of humans, animals, and phlebotomine sand flies with the Alagoas serotype of vesicular stomatitis virus in Colombia","volume":"36","author":"Tesh","year":"1987","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jvacx.2019.100009_b0405","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1126\/science.287.5452.485","article-title":"Transmission of vesicular stomatitis virus from infected to noninfected black flies co-feeding on nonviremic deer mice","volume":"287","author":"Mead","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.jvacx.2019.100009_b0410","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/oxfordjournals.aje.a120738","article-title":"The epizootiology of the vesicular stomatitis viruses: a reappraisal","volume":"86","author":"Jonkers","year":"1967","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jvacx.2019.100009_b0415","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1128\/jvi.51.1.208-214.1984","article-title":"Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo","volume":"51","author":"Lefrancois","year":"1984","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2019.100009_b0420","doi-asserted-by":"crossref","first-page":"11079","DOI":"10.1128\/JVI.75.22.11079-11087.2001","article-title":"Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge","volume":"75","author":"Kahn","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2019.100009_b0425","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiv257","article-title":"Characterization of a bivalent vaccine capable of inducing protection against both Ebola and cross-clade H5N1 influenza in mice","author":"Wong","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jvacx.2019.100009_b0430","doi-asserted-by":"crossref","DOI":"10.1038\/nm1258","article-title":"Live attenuated vaccine protects nonhuman primates against Ebola and Marburg viruses","author":"Jones","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.jvacx.2019.100009_b0435","unstructured":"Merck & Co., Inc., Kenilworth, NJ, USA and NewLink Genetics Corp., unpublished data."},{"key":"10.1016\/j.jvacx.2019.100009_b0440","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0092-8674(84)90041-2","article-title":"Vesicular stomatitis virus defective interfering particles can contain extensive genomic sequence rearrangements and base substitutions","volume":"36","author":"O\u2019Hara","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.jvacx.2019.100009_b0445","doi-asserted-by":"crossref","first-page":"e1000225","DOI":"10.1371\/journal.ppat.1000225","article-title":"Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates","volume":"4","author":"Geisbert","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jvacx.2019.100009_b0450","doi-asserted-by":"crossref","first-page":"S1075","DOI":"10.1093\/infdis\/jir349","article-title":"Recombinant vesicular stomatitis virus\u2013based vaccines against Ebola and Marburg virus infections","volume":"204","author":"Geisbert","year":"2011","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.jvacx.2019.100009_b0455","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.vetmic.2012.08.023","article-title":"Stability and inactivation of vesicular stomatitis virus, a prototype rhabdovirus","volume":"162","author":"Zimmer","year":"2013","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.jvacx.2019.100009_b0460","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3201\/eid2104.142012","article-title":"Safety of recombinant VSV\u2013Ebola virus vaccine vector in pigs","volume":"21","author":"de Wit","year":"2015","journal-title":"Emerg Infect Dis."},{"key":"10.1016\/j.jvacx.2019.100009_b0465","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1128\/jcm.6.4.437-438.1977","article-title":"Vesicular stomatitis virus causes abortion and neonatal death in ferrets","volume":"6","author":"Suffin","year":"1977","journal-title":"J Clin Microbiol"},{"issue":"Suppl. 3","key":"10.1016\/j.jvacx.2019.100009_b0470","doi-asserted-by":"crossref","first-page":"S1090","DOI":"10.1093\/infdis\/jir379","article-title":"Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the syrian hamster model of lethal Ebola virus infection","volume":"204","author":"Tsuda","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jvacx.2019.100009_b0475","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1128\/JVI.01860-12","article-title":"A chimeric Vesiculo\/Alphavirus is an effective alphavirus vaccine","volume":"87","author":"Chattopadhyay","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2019.100009_b0480","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3201\/eid2102.141649","article-title":"Vesicular Stomatitis virus\u2013based vaccines against Lassa and Ebola Viruses","volume":"21","author":"Marzi","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jvacx.2019.100009_b0485","unstructured":"Merck & Co., Inc., Kenilworth, NJ, USA, Investigators Brochure Version 4. 2017, IND # 16131."},{"key":"10.1016\/j.jvacx.2019.100009_b0490","unstructured":"Jones S, Feldmann H, Stroeher U. Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers. US Patent 8,012,489 Sept. 6; 2011."},{"key":"10.1016\/j.jvacx.2019.100009_b0495","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1128\/JVI.76.3.1309-1327.2002","article-title":"Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein","volume":"76","author":"van den Pol","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2019.100009_b0500","first-page":"28","article-title":"Experimental intracerebral infection of horses, cattle, and sheep with the virus of vesicular stomatitis","author":"Frank","year":"1945","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.jvacx.2019.100009_b0505","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/rmv.661","article-title":"Prospects for immunisation against Marburg and Ebola viruses","volume":"20","author":"Geisbert","year":"2010","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.jvacx.2019.100009_b0510","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aab3920","article-title":"VSV-EBOV rapidly protects macaques against infection with the current Ebola virus outbreak strain","volume":"349","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jvacx.2019.100009_b0515","doi-asserted-by":"crossref","first-page":"158ra146","DOI":"10.1126\/scitranslmed.3004582","article-title":"Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates","volume":"4","author":"Wong","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jvacx.2019.100009_b0520","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1016\/j.vaccine.2014.08.028","article-title":"Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents","volume":"32","author":"Wong","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2019.100009_b0525","doi-asserted-by":"crossref","unstructured":"C.E. Mire J.B. Geisbert, K.N. Agans et al. Durability of a vesicular stomatitis virus-based Marburg virus vaccine in nonhuman primates PLoS One 9 4 e94355","DOI":"10.1371\/journal.pone.0094355"},{"key":"10.1016\/j.jvacx.2019.100009_b0530","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1128\/JVI.00342-11","article-title":"Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime\u2013boost vaccine regimen","volume":"85","author":"Schell","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.jvacx.2019.100009_b0535","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1128\/JVI.03361-12","article-title":"Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with Ebolavirus","volume":"87","author":"Herbert","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2019.100009_b0540","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1128\/JVI.73.5.3723-3732.1999","article-title":"Attenuated vesicular stomatitis viruses as vectors","volume":"73","author":"Roberts","year":"1999","journal-title":"J Virol"},{"issue":"Suppl. 3","key":"10.1016\/j.jvacx.2019.100009_b0545","doi-asserted-by":"crossref","first-page":"S1066","DOI":"10.1093\/infdis\/jir348","article-title":"Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy","volume":"204","author":"Marzi","year":"2011","journal-title":"J Infect Dis."},{"key":"10.1016\/j.jvacx.2019.100009_b0550","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.virol.2005.06.016","article-title":"Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine","volume":"340","author":"Kapadia","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.jvacx.2019.100009_b0555","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1128\/JVI.72.6.4704-4711.1998","article-title":"Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge","volume":"72","author":"Roberts","year":"1998","journal-title":"J Virol"},{"issue":"Suppl. 2","key":"10.1016\/j.jvacx.2019.100009_b0560","doi-asserted-by":"crossref","first-page":"S443","DOI":"10.1093\/infdis\/jiv316","article-title":"Vaccination with a highly attenuated recombinant vesicular stomatitis virus vector protects against challenge with a lethal dose of Ebola virus","volume":"212","author":"Matassov","year":"2015","journal-title":"J Infect Dis."},{"issue":"004","key":"10.1016\/j.jvacx.2019.100009_b0565","first-page":"2157","article-title":"Falzarano D Vesicular stomatitis virus based vaccines for prophylaxis and treatment of filovirus infections","volume":"S1","author":"Marzi","year":"2011","journal-title":"J Bioterror Biodef"},{"key":"10.1016\/j.jvacx.2019.100009_b0570","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"A phase 2 placebo-controlled clinical trial of 2 vaccines to prevent Ebola in Liberia","volume":"377","author":"Kennedy","year":"2017","journal-title":"New Eng J Med"},{"key":"10.1016\/j.jvacx.2019.100009_b0575","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1128\/JVI.78.8.3930-3940.2004","article-title":"Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol","volume":"78","author":"Ramsburg","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2019.100009_b0580","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0092-8674(01)00482-2","article-title":"An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants","volume":"106","author":"Rose","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.jvacx.2019.100009_b0585","unstructured":"Merck & Co., Inc., Kenilworth, NJ, USA Clinical Study Report V920-10 A Randomized Trial to Evaluate Ebola Vaccine Efficacy and Safety in Guinea, West Africa."},{"key":"10.1016\/j.jvacx.2019.100009_b0590","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/jama.2015.1995","article-title":"Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick","volume":"313","author":"Lai","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jvacx.2019.100009_b0595","doi-asserted-by":"crossref","first-page":"E819","DOI":"10.1503\/cmaj.170074","article-title":"A phase 1 randomized, placebo controlled clinical trial assessing the safety and immunogenicity of a recombinant vesicular stomatitis virus Ebola vaccine in healthy adults","volume":"189","author":"ElSherif","year":"2017","journal-title":"Canad Med Assn J"},{"key":"10.1016\/j.jvacx.2019.100009_b0600","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/infdis\/jix189","article-title":"Six-month safety data of Ebola Zaire vaccine (rVSV\u0394G-ZEBOV-GP) in a phase III double blind, placebo controlled randomized study in healthy adults","volume":"215","author":"Halperin","year":"2017","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.jvacx.2019.100009_b0605","doi-asserted-by":"crossref","first-page":"e1002402","DOI":"10.1371\/journal.pmed.1002402","article-title":"Safety and immunogenicity of rVSV\u0394G-ZEBOV-GP Ebola vaccine in adults and children in Lambar\u00e9n\u00e9, Gabon: a phase I randomised trial","volume":"14","author":"Agnandji","year":"2017","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.jvacx.2019.100009_b0610","doi-asserted-by":"crossref","first-page":"ofv082","DOI":"10.1093\/ofid\/ofv082","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency virus-1 gag vaccine (HVTN 090)","volume":"2","author":"Fuchs","year":"2015","journal-title":"Open Forum Infect Dis"},{"issue":"385","key":"10.1016\/j.jvacx.2019.100009_b0615","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj1701","article-title":"Plasma signature of the safety of the VSV Ebola vaccine in Europe and Africa. A dose-dependent plasma signature of innate immune responses to the VSV-Ebola vaccine reflects its biological outcomes and safety in Europe and Africa","volume":"9","author":"Huttner","year":"2017","journal-title":"Science Trans Med"},{"issue":"Suppl. 1","key":"10.1016\/j.jvacx.2019.100009_b0620","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/infdis\/jiy020","article-title":"The Sierra Leone trial to introduce a vaccine Against Ebola: An evaluation of rVSV\u0394G-ZEBOV-GP vaccine tolerability and safety during the West Africa Ebola outbreak","volume":"217","author":"Samai","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jvacx.2019.100009_b0625","unstructured":"WHO. SAGE Report 18 October 2018. <http:\/\/www.who.int\/immunization\/policy\/sage\/summary_sageoct18_report.pdf?ua=1>."}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136219300105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136219300105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:02:36Z","timestamp":1762912956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136219300105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":124,"alternative-id":["S2590136219300105"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2019.100009","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"rVSV\u0394G-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk\/benefit assessment","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2019.100009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100009"}}